In major move, patent of Novartis' blockbuster cardiac drug revoked by India

The Indian Patent Office revoked Novartis' patent for Vymada, a heart failure drug, citing a lack of novelty and inventive step. This decision paves the way for generic versions, potentially lowering treatment costs for Indian patients. Domestic pharmaceutical companies had challenged the patent, arguing it violated Section 3(d) of the Patents Act, which prevents 'evergreening'.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wnIFz8S
via IFTTT